Albrecht Joerg, Werth Victoria P
Department of Medicine, Division of Dermatology, John Stroger Jr. Hospital of Cook County, Chicago, Illinois, USA.
Dermatol Ther. 2007 Mar-Apr;20(2):93-101. doi: 10.1111/j.1529-8019.2007.00117.x.
Skin involvement is a frequent presenting manifestation of systemic lupus erythematosus (SLE). Cutaneous lupus erythematosus (CLE), frequently occurring without SLE, may be even more common than SLE. Until recently, clinical instruments to measure skin involvement in CLE did not exist, hampering clinical research in this field. In this paper the present authors describe outcome instruments for SLE and outline the considerations underlying the design and validation of an outcome instrument for CLE, the cutaneous lupus disease area and severity index. These studies serve as a model for development and validation of standardized instruments that can be applied to other cutaneous diseases, particularly autoimmune diseases, in order to facilitate epidemiologic studies and clinical trials.
皮肤受累是系统性红斑狼疮（SLE）常见的临床表现。皮肤型红斑狼疮（CLE）常不伴有SLE单独出现，其发病率可能比SLE更高。直到最近，仍没有用于测量CLE皮肤受累情况的临床工具，这阻碍了该领域的临床研究。在本文中，作者描述了SLE的疗效评估工具，并概述了用于CLE的疗效评估工具——皮肤狼疮疾病面积和严重程度指数（Cutaneous Lupus Disease Area and Severity Index）设计与验证的相关考量因素。这些研究为标准化工具的开发和验证提供了范例，这些工具可应用于其他皮肤疾病，尤其是自身免疫性疾病，以促进流行病学研究和临床试验。
